

(PCT Article 36 and Rule 70)

Date of submission of the demand	Date of completion of this report
Name and mailing address of the IPEA/IP	Authorized officer
Facsimile No.	Telephone No.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/JP2005/002539

Box No. I Basis of the report

1. With regard to the **language**, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.
- ☐ This report is based on translations from the original language into the following _____, which is the language of a translation furnished for the purposes of:
- ☐ international search (Rule 12.3 and 23.1(b))
- ☐ publication of the international application (Rule 12.4)
- ☐ international preliminary examination (Rule 55.2 and/or 55.3)
2. With regard to the **elements** of the international application, this report is based on *(replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report)*:
- ☐ the international application as originally filed/furnished
- ☒ the description:
- pages 1-7 _____ as originally filed/furnished
- pages* _____ received by this Authority on _____
- pages* _____ received by this Authority on _____
- ☒ the claims:
- nos. _____ as originally filed/furnished
- nos.* _____ as amended (together with any statement) under Article 19
- nos.* 1-4 _____ received by this Authority on 22.07.2005
- nos.* _____ received by this Authority on _____
- ☐ the drawings:
- sheets _____ as originally filed/furnished
- sheets* _____ received by this Authority on _____
- sheets* _____ received by this Authority on _____
- ☐ a sequence listing and/or any related table(s) – see Supplemental Box Relating to Sequence Listing.
3. ☐ The amendments have resulted in the cancellation of:
- ☐ the description, pages _____
- ☐ the claims, nos. _____
- ☐ the drawings, sheets/figs _____
- ☐ the sequence listing (*specify*): _____
- ☐ any table(s) related to sequence listing (*specify*): _____
4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).
- ☐ the description, pages _____
- ☐ the claims, nos. _____
- ☐ the drawings, sheets/figs _____
- ☐ the sequence listing (*specify*): _____
- ☐ any table(s) related to sequence listing (*specify*): _____

* If item 4 applies, some or all of those sheets may be marked "superseded."

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/JP2005/002539

Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement		
1. Statement			
Novelty (N)	Claims	<u>1-4</u>	YES
	Claims		NO
Inventive step (IS)	Claims	<u>1-4</u>	YES
	Claims		NO
Industrial applicability (IA)	Claims	<u>1-4</u>	YES
	Claims		NO
2. Citations and explanations (Rule 70.7)			
<p>Documents cited in the international search report:</p> <p>Document 1: JP 7-242547 A (Sanwa Kagaku Kenkyusho Co., Ltd.), 19 September 1995, entire document</p> <p>Document 2: JP 61-200991 A (Sanwa Kagaku Kenkyusho Co., Ltd.), 5 September 1986, entire document</p> <p>Document 3: JP 63-57588 A (Sanwa Kagaku Kenkyusho Co., Ltd.), 12 March 1988, entire document</p> <p>Document 4: JP 2001-10975 A (Takeda Chemical Industries, Ltd.), 16 January 2001, entire document</p>			
<p>Document 1 indicates that the compounds set forth in claims 1 and 2 of this application are used as an agent to inhibit the development and as an agent to treat diabetic simple retinopathy, and documents 2 and 3 indicate that the compounds set forth in claims 1 and 2 are used as agents for the treatment and prevention of diabetic retinopathy. However, none of the documents indicates or suggests that the compounds set forth in claims 1 and 2 of this application are used as agents for the treatment of severe diabetic retinopathy (agents to inhibit the development to diabetic proliferative retinopathy, agents to inhibit the development of diabetic preproliferative retinopathy, and agents to</p>			

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/JP2005/002539

Box No. V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;
citations and explanations supporting such statement

inhibit the development of diabetic proliferative retinopathy). In addition, document 4 indicates that compounds having an angiotensin II antagonist effect are used as agents to prevent, treat or inhibit the development of simple retinopathy or preproliferative retinopathy, but neither indicates nor discloses that the compounds set forth in claims 1 and 2 of this application are used.

Therefore the inventions set forth in claims 1 to 4 are novel and involve an inventive step in relation to documents 1 to 4.